Hotelbuchung
Hotel Registration
Grußwort
Welcome address
Beteiligte Gesellschaften
Societies involved
DOG Information
DOG Information
Eröffnung des Kongresses
Opening Ceremony
Preise
Awards
Ablauf der Tagung 2003
General overview of congress
Lageplan der Räumlichkeiten
Map of Congress Center
Wissenschaftliche Themen
Scientific topics
Symposien
Symposia
Wissenschaftliches Programm
Scientific program
Posterpräsentationen
Poster Presentation
Kurse
Courses
Begleitende Veranstaltungen
Accompanying program
Arbeitssitzungen
Working sessions
Rahmenprogramm
Social program
Allgemeine Informationen
General Information
Autorenindex
Index of Authors
Industrieaussteller
Commercial exhibitors
Sponsoren
Sponsors
Impressum
DOG Homepage
Abstract
Abstract
FTY720 Prolongs Clear Corneal Allograft Survival with a Differential Effect on Different Lymphocyte Populations
Mayer K.1, Birnbaum F.1, Reinhard T.1, Reis A.1, Braunstein S.3, Claas F.4, Sundmacher R.1
1Eye Hospital, 3Departement of Pathology, Heinrich-Heine University, Duesseldorf; 2Eye Hospital, Albert-Ludwigs-University, Freiburg; 4Department of Immunohematology and Blood Transfusion, Leiden University Medical Center, Leiden, The Netherlands
Purpose: FTY720 is a potent immunomodulator with unique effects on lymphocyte homing and has recently proven to be safe and effective in renal transplantation in man. We investigated the potency of FTY720 in inhibiting allograft rejection in the rat keratoplasty model.
Method: Penetrating keratoplasties were performed using Fisher rats as donors and Lewis rats as recipients or donors: group 1 (n= 10): allogeneic control; group 2 (n= 10): Lewis/Lewis syngeneic control; group 3 (n= 9): mycophenolate mofetile 40 mg/kg; group 4 (n= 10): FTY720 1.2 mg/kg; group 5 (n= 8): FTY720 0.3 mg/kg. Four animals of each group were sacrificed for immunohistological evaluation on day 14. Medication in the therapy groups was given for the duration of 18 days.
Results: The mean rejection free graft survival time was 11.3 (±0.8) days for the allogeneic control (group 1), 24.6 (± 2.5) days for group 3 (MMF 40 mg/kg), 44.5 (± 5.7) days for group 4 (FTY720 1.2mg/kg) and 35.3 (± 5.7) days for group 5 (FTY720 0.3 mg/kg) (p<